Sara Bonstein Sells 3,470 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 3,470 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00. Following the completion of the transaction, the chief financial officer now owns 114,736 shares of the company’s stock, valued at $7,538,155.20. This represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The shares were sold at an average price of $63.72, for a total value of $67,925.52.

Insmed Stock Down 0.7 %

Shares of NASDAQ INSM opened at $65.25 on Friday. The stock has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53. The firm has a 50-day moving average price of $71.23 and a 200 day moving average price of $72.44. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same period last year, the firm posted ($1.10) EPS. Equities research analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Institutional Trading of Insmed

Large investors have recently bought and sold shares of the company. Victory Capital Management Inc. raised its stake in shares of Insmed by 672.7% during the 2nd quarter. Victory Capital Management Inc. now owns 147,140 shares of the biopharmaceutical company’s stock worth $9,858,000 after buying an additional 128,098 shares during the last quarter. Private Advisor Group LLC acquired a new position in Insmed during the second quarter worth about $575,000. Los Angeles Capital Management LLC purchased a new stake in shares of Insmed in the second quarter valued at about $258,000. ClariVest Asset Management LLC acquired a new stake in shares of Insmed in the second quarter valued at approximately $738,000. Finally, American Century Companies Inc. increased its stake in shares of Insmed by 7.5% during the 2nd quarter. American Century Companies Inc. now owns 755,271 shares of the biopharmaceutical company’s stock worth $50,603,000 after purchasing an additional 52,647 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have weighed in on INSM. Bank of America boosted their price objective on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. JPMorgan Chase & Co. upped their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. Truist Financial restated a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.